133 related articles for article (PubMed ID: 30845102)
1. Fostamatinib (Tavalisse) for ITP.
Med Lett Drugs Ther; 2019 Feb; 61(1566):28-30. PubMed ID: 30845102
[No Abstract] [Full Text] [Related]
2. Fostamatinib for the treatment of chronic immune thrombocytopenia.
Connell NT; Berliner N
Blood; 2019 May; 133(19):2027-2030. PubMed ID: 30803989
[TBL] [Abstract][Full Text] [Related]
3. Fostamatinib for the treatment of immune thrombocytopenia in adults.
Moore DC; Gebru T; Muslimani A
Am J Health Syst Pharm; 2019 May; 76(11):789-794. PubMed ID: 30951590
[TBL] [Abstract][Full Text] [Related]
4. Fostamatinib: First Global Approval.
Markham A
Drugs; 2018 Jun; 78(9):959-963. PubMed ID: 29869203
[TBL] [Abstract][Full Text] [Related]
5. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials.
Bussel J; Arnold DM; Grossbard E; Mayer J; Treliński J; Homenda W; Hellmann A; Windyga J; Sivcheva L; Khalafallah AA; Zaja F; Cooper N; Markovtsov V; Zayed H; Duliege AM
Am J Hematol; 2018 Jul; 93(7):921-930. PubMed ID: 29696684
[TBL] [Abstract][Full Text] [Related]
6. Prucalopride succinate, Fostamatinib disodium hexahydrate, Avatrombopag maleate, and Lusutrombopag.
Hussar DA; Kludjian GA
J Am Pharm Assoc (2003); 2019; 59(4):601-604. PubMed ID: 31296323
[No Abstract] [Full Text] [Related]
7. Fostamatinib for persistent/chronic adult immune thrombocytopenia.
Newland A; Lee EJ; McDonald V; Bussel JB
Immunotherapy; 2018 Jan; 10(1):9-25. PubMed ID: 28967793
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic options for adult patients with previously treated immune thrombocytopenia - a systematic review and network meta-analysis.
Yang R; Lin L; Yao H; Ji O; Shen Q
Hematology; 2019 Dec; 24(1):290-299. PubMed ID: 30661482
[TBL] [Abstract][Full Text] [Related]
9. Real-World Use of Fostamatinib in Patients with Immune Thrombocytopenia and Thrombotic Risk.
Mehta AR; Kefela A; Toste C; Sweet D
Acta Haematol; 2022; 145(2):221-228. PubMed ID: 34913873
[TBL] [Abstract][Full Text] [Related]
10. Long-term sustained response to fostamatinib in two patients with chronic refractory immune thrombocytopenia (ITP).
Lee EJ; Izak M; Bussel JB
Br J Haematol; 2020 Apr; 189(2):379-382. PubMed ID: 31900937
[TBL] [Abstract][Full Text] [Related]
11. Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases.
Bajpai M
IDrugs; 2009 Mar; 12(3):174-85. PubMed ID: 19333898
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Flinn IW; Bartlett NL; Blum KA; Ardeshna KM; LaCasce AS; Flowers CR; Shustov AR; Thress KS; Mitchell P; Zheng F; Skolnik JM; Friedberg JW
Eur J Cancer; 2016 Feb; 54():11-17. PubMed ID: 26707592
[TBL] [Abstract][Full Text] [Related]
13. Evaluating fostamatinib disodium as a treatment option for immune thrombocytopenia in adult patients.
Dierickx D; Neefs J
Expert Opin Pharmacother; 2022 Jun; 23(8):885-892. PubMed ID: 35621338
[TBL] [Abstract][Full Text] [Related]
14. New Small Molecule Drugs for Thrombocytopenia: Chemical, Pharmacological, and Therapeutic Use Considerations.
Clemons Bankston P; Al-Horani RA
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31226783
[TBL] [Abstract][Full Text] [Related]
15. Spleen tyrosine kinase inhibition: a new promising approach to chronic and refractory immune thrombocytopenia.
Niscola P; Scaramucci L; Giovannini M
Immunotherapy; 2018 Jan; 10(1):5-7. PubMed ID: 29192558
[No Abstract] [Full Text] [Related]
16. A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-α antagonist.
Genovese MC; van der Heijde DM; Keystone EC; Spindler AJ; Benhamou C; Kavanaugh A; Fudman E; Lampl K; O'Brien C; Duffield EL; Poiley J; Weinblatt ME
J Rheumatol; 2014 Nov; 41(11):2120-8. PubMed ID: 25225285
[TBL] [Abstract][Full Text] [Related]
17. Promising new treatments for rheumatoid arthritis - the kinase inhibitors.
Yazici Y; Regens AL
Bull NYU Hosp Jt Dis; 2011; 69(3):233-7. PubMed ID: 22035435
[TBL] [Abstract][Full Text] [Related]
18. Eltrombopag in chronic idiopathic thrombocytopenic purpura and HCV-related thrombocytopenia.
Panzer S
Drugs Today (Barc); 2009 Feb; 45(2):93-9. PubMed ID: 19343229
[TBL] [Abstract][Full Text] [Related]
19. Kinase inhibitors for the treatment of rheumatoid arthritis.
Yazici Y; Steiger B
Bull NYU Hosp Jt Dis; 2012; 70(3):204-7. PubMed ID: 23259630
[TBL] [Abstract][Full Text] [Related]
20. Fostamatinib disodium hexahydrate: a novel treatment for adult immune thrombocytopenia.
McBride A; Nayak P; Kreychman Y; Todd L; Duliege AM; Mehta AR
Am J Manag Care; 2019 Nov; 25(19 Suppl):S347-S358. PubMed ID: 31809006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
